Antitumor agent for thyroid cancer
US9006256B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Apr 8, 2011 |
| Grant date | Apr 14, 2015 |
| Priority date | — |
| Expiry date | Jun 18, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/106
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides pharmaceutical compositions and therapeutic methods for treating diseases such as multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract. The therapeutic methods and pharmaceutical compositions use a RET kinase inhibiting substance, such as 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and pharmacologically acceptable salts thereof, and involve a step of administering the RET kinase inhibiting substance to a patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.